1 University of Tennessee College of Medicine, Memphis, TN [email protected]
2 State University of New York at Stony Brook School of Medicine, Stony Brook, NY
3 Northwestern University Feinberg School of Medicine, Chicago, IL
Dr. DeVincenzo reports receiving research grants, through the University of Tennessee, from AstraZeneca (the manufacturer of palivizumab), research grants and consulting fees from Alios BioPharma, Biota, Gilead Sciences, Janssen, and Teva Pharmaceuticals, consulting fees from Merck, and research grants from Pulmocide and Regeneron Pharmaceuticals (all of which have research interests involving respiratory syncytial virus and all of which are competitive with AstraZeneca); and Dr. Yogev, receiving speaking fees from AstraZeneca. No other potential conflict of interest relevant to this letter was reported.
